Aligos Therapeutics (NASDAQ:ALGS) Issues Earnings Results, Beats Estimates By $0.19 EPS

Aligos Therapeutics (NASDAQ:ALGS) announced its earnings results on Friday. The company reported ($2.09) earnings per share for the quarter, beating the consensus estimate of ($2.28) by $0.19, FiscalAI reports. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%. The company had revenue of $2.87 million for the quarter, compared to the consensus estimate of $4.85 million.

Aligos Therapeutics Price Performance

Aligos Therapeutics stock opened at $4.07 on Friday. The stock’s fifty day moving average price is $5.31 and its two-hundred day moving average price is $6.17. The firm has a market cap of $25.40 million, a PE ratio of -0.56 and a beta of 2.43. Aligos Therapeutics has a one year low of $3.98 and a one year high of $13.69.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Weiss Ratings downgraded Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. HC Wainwright restated a “buy” rating on shares of Aligos Therapeutics in a research note on Monday, August 10th. Finally, Jefferies Financial Group raised shares of Aligos Therapeutics to a “strong-buy” rating in a report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.50.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.